Loading..

Merus N.V. (MRUS) Report Analysis

Corporate Events

Positive

Merus N.V. Presents Clinical Data on Zenocutuzu...

2022-06-05 15:00:00

Merus N.V. announced interim efficacy data as of an April 12, 2022 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (...

Neutral

Merus N.V. Presents at 2022 Jefferies Global He...

2022-06-03 09:33:00

Merus N.V. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 12:45 PM. Venue: Marriott Marquis, New York City, New York, Un...

Neutral

Merus N.V. Presents at H.C. Wainwright Global I...

2022-05-17 08:45:00

Merus N.V. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 C...

Neutral

Merus N.V. - Special Call

2022-05-09 20:29:00

To discuss the Zeno clinical data and provide a program update

Neutral

Merus N.V. - Shareholder/Analyst Call

2022-04-29 12:15:00

AGM

Neutral

Merus N.V., Annual General Meeting, May 31, 2022

2022-04-29 12:15:00

Merus N.V., Annual General Meeting, May 31, 2022, at 15:00 Central European Standard Time. Agenda: To consider discussion of the Dutch statuto...

Neutral

Merus N.V. Presents at PEGS Boston Conference 2...

2022-04-23 07:37:00

Merus N.V. Presents at PEGS Boston Conference 2022, May-03-2022 05:00 PM. Venue: Boston, Massachusetts, United States. Speakers: Pieter Fokko ...

Neutral

Merus N.V. Presents at Needham 21st Annual Heal...

2022-04-06 12:00:00

Merus N.V. Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 10:15 AM. Speakers: Sven Ante Lundberg, CEO, President, Principa...

Neutral

Merus N.V. Presents at 14th Kempen Life Science...

2022-03-29 06:52:00

Merus N.V. Presents at 14th Kempen Life Sciences Conference, Apr-20-2022 . Venue: Amsterdam, Netherlands.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Needham & Company, LLC, Needham 21st Annual Hea...

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

Merus N.V. Presents at 4th Annual Guggenheim On...

2022-02-03 13:00:00

Merus N.V. Presents at 4th Annual Guggenheim Oncology Day, Feb-10-2022 10:30 AM. Speakers: Bill Lundberg, President, Chief Executive Officer.

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenhe...

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Neutral

Cambridge Innovation Institute, LLC, PEGS Bosto...

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Positive

Merus N.V.(NasdaqGM:MRUS) added to NASDAQ Biote...

2021-12-20 00:00:00

Merus N.V. has been added to NASDAQ Biotechnology Index.

Positive

Merus N.V. Presents Updated Analysis of Zenocut...

2021-12-10 13:00:00

Merus N.V. presented clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients (pts) with HER2 positiv...

Neutral

Kempen & Co, 14th Kempen Life Sciences Conferen...

2021-11-13 00:00:00

Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022. Venue: Amsterdam, Netherlands.

Neutral

Merus N.V. Presents at 12th Annual Jefferies Gl...

2021-11-10 13:11:00

Merus N.V. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Negative

Merus N.V. has filed a Follow-on Equity Offering.

2021-11-04 00:00:00

Merus N.V. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock

Negative

Merus N.V. has completed a Follow-on Equity Off...

2021-11-04 00:00:00

Merus N.V. has completed a Follow-on Equity Offering in the amount of $110.000025 million. Security Name: Common Stock Security Type: Comm...

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Positive

Merus N.V. Presents Early Clinical Data on MCLA...

2021-10-07 13:00:00

Merus N.V. presented clinical data on MCLA-158, including clinical responses observed in advanced head and neck squamous cell carcinoma (HNSCC...

Neutral

Merus N.V. Presents at 2021 AACR-NCI-EORTC Virt...

2021-09-30 20:35:00

Merus N.V. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-07-2021 09:00 AM.

Neutral

Merus N.V. Presents at Cantor Global Healthcare...

2021-09-07 12:00:00

Merus N.V. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 02:40 PM. Venue: New York, United States. Speakers: Bill Lundberg...

Neutral

Merus N.V. Presents at H.C. Wainwright 23rd Ann...

2021-09-07 12:00:00

Merus N.V. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New...

Neutral

Merus N.V. Presents at Citi’s 16th Annual BioPh...

2021-09-01 18:36:00

Merus N.V. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021 01:25 PM. Venue: New York, United States. Speakers: Bill L...

Neutral

American Association For Cancer Research, Natio...

2021-08-11 12:00:00

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2...

Positive

Merus N.V. Announces Publication in Nature Comm...

2021-07-21 12:00:00

Merus N.V. announced the novel mechanism of action (MOA) of MCLA-145, the Company’s clinical stage Biclonics® T-cell agonist. MCLA-145 binds w...

Neutral

Merus N.V. Presents at Cambridge Health Institu...

2021-07-16 13:36:00

Merus N.V. Presents at Cambridge Health Institute PEGS Virtual Conference, Jul-19-2021 through Jul-22-2021. Presentation Date & Speakers: Jul-...

Neutral

Cambridge Healthtech Institute, Inc., Cambridge...

2021-07-16 12:52:00

Cambridge Healthtech Institute, Inc., Cambridge Health Institute PEGS Virtual Conference, Jul 19, 2021 through Jul 22, 2021.

Neutral

Merus N.V. Presents at William Blair Biotech Fo...

2021-07-07 20:20:00

Merus N.V. Presents at William Blair Biotech Focus Conference 2021, Jul-14-2021 11:20 AM. Speakers: Sven Ante Lundberg, CEO, President, Princi...

Positive

Merus N.V. Presents Clinical Data on Zenocutuzumab in NRG1-Fusion Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

2022-06-05 15:00:00

Merus N.V. announced interim efficacy data as of an April 12, 2022 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody Zeno in patients with NRG1+ cancer presented virtually by Lead Author, Dr. Alison Schram of Memorial Sloan Kettering Cancer Center (MSKCC) at the 2022 ASCO Annual meeting. Key findings of the presentation include: As of April 12, 2022, 110 patients were treated with Zeno; Efficacy was assessed in 79 evaluable patients with measurable disease having the opportunity for 6 months or more follow-up and who met the criteria for the primary analysis population; Median age was 59 years (range of 22-84); 59% were female; Median number of prior lines of systemic therapy was 2, (range of 0-8); Qualifying NRG1 fusions included 26 distinct fusion partners; ORR per RECIST criteria as assessed by investigator was 34% (95% Cl; 24%-46%) across multiple tumor types: PDAC ORR 42% (8/19) and NSCLC ORR 35% (16/46); Tumor shrinkage was observed in 70% of patients; Median time to response was 1.8 months, and median duration of exposure was 6.3 months; Median duration of response was 9.1 months, and 20/83 patients were continuing treatment as of the cutoff date; Strong safety profile with a low incidence of Grade 3 or higher treatment-related adverse events, including low rates of severe gastrointestinal and dermatologic toxicity, without clinically significant cardiotoxicity.

Neutral

Merus N.V. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 12:45 PM

2022-06-03 09:33:00

Merus N.V. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 12:45 PM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Sven Ante Lundberg, CEO, President, Principal Financial Officer & Executive Director.

Neutral

Merus N.V. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM

2022-05-17 08:45:00

Merus N.V. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: Bill Lundberg, President, Chief Executive Officer.

Neutral

Merus N.V. - Special Call

2022-05-09 20:29:00

To discuss the Zeno clinical data and provide a program update

Neutral

Merus N.V. - Shareholder/Analyst Call

2022-04-29 12:15:00

AGM

Neutral

Merus N.V., Annual General Meeting, May 31, 2022

2022-04-29 12:15:00

Merus N.V., Annual General Meeting, May 31, 2022, at 15:00 Central European Standard Time. Agenda: To consider discussion of the Dutch statutory annual report over the financial year 2021; to consider adoption of the Dutch statutory annual accounts over the financial year 2021; to consider explanation of the dividend and reservation policy; to consider release of each member of our board of directors from liability for the exercise of their duties; to consider Granting authorization to acquire shares (or depository receipts for such shares) in the Company’s capital.

Neutral

Merus N.V. Presents at PEGS Boston Conference 2022, May-03-2022 05:00 PM

2022-04-23 07:37:00

Merus N.V. Presents at PEGS Boston Conference 2022, May-03-2022 05:00 PM. Venue: Boston, Massachusetts, United States. Speakers: Pieter Fokko van Loo, Senior Director, Oncology Immunology.

Neutral

Merus N.V. Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 10:15 AM

2022-04-06 12:00:00

Merus N.V. Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 10:15 AM. Speakers: Sven Ante Lundberg, CEO, President, Principal Financial Officer & Executive Director.

Neutral

Merus N.V. Presents at 14th Kempen Life Sciences Conference, Apr-20-2022

2022-03-29 06:52:00

Merus N.V. Presents at 14th Kempen Life Sciences Conference, Apr-20-2022 . Venue: Amsterdam, Netherlands.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Neutral

Merus N.V. Presents at 4th Annual Guggenheim Oncology Day, Feb-10-2022 10:30 AM

2022-02-03 13:00:00

Merus N.V. Presents at 4th Annual Guggenheim Oncology Day, Feb-10-2022 10:30 AM. Speakers: Bill Lundberg, President, Chief Executive Officer.

Neutral

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022

2022-01-24 11:50:00

Guggenheim Securities, LLC, 4th Annual Guggenheim Oncology Day, Feb 09, 2022 through Feb 11, 2022.

Neutral

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022

2022-01-13 18:45:00

Cambridge Innovation Institute, LLC, PEGS Boston Conference 2022, May 02, 2022 through May 06, 2022. Venue: Boston, Massachusetts, United States.

Positive

Merus N.V.(NasdaqGM:MRUS) added to NASDAQ Biotechnology Index

2021-12-20 00:00:00

Merus N.V. has been added to NASDAQ Biotechnology Index.

Positive

Merus N.V. Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at San Antonio Breast Cancer Symposium

2021-12-10 13:00:00

Merus N.V. presented clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who had progressed on anti-HER2 antibody drug conjugates (ADC), at the San Antonio Breast Cancer Symposium in San Antonio, Texas. The reported data are from the completed phase 2 study, designed to explore the efficacy of a triplet combination of Zeno plus trastuzumab and vinorelbine in MBC patients (NCT03321981). Preliminary results for patients treated with the triplet regimen were presented at the American Society of Clinical Oncology 2020 Annual Meeting. The combination was observed to be well-tolerated in the run-in cohort and the cohort was expanded. The primary endpoint of the study was clinical benefit rate (CBR) at 24 weeks of 45%. Updated results from the cohort expansion are presented here: at the efficacy data cut-off, March 31, 2021, 39 patients, with a median age of 57 and with a median number of five prior therapies, had received the Zeno-based triplet combination, 4 of whom were ongoing. All patients had completed at least 6 months of treatment or discontinued; 37 patients with locally confirmed HER2 overexpression (IHC 3+ or IHC 2+/FISH-positive) were evaluable for antitumor activity; the clinical benefit rate (CBR: complete response + partial response + stable disease =24 weeks) per investigator assessment was 49% (18/37 patients; 90% CI 34 - 63); confirmed responses (per investigator) were reported in 10 patients, including 2 patients with complete response (CR); median duration of response was 4.2 months (90% CI 2.8 - 12.4), including 2 patients with CR lasting 4.2 and 7.2+ months, and 8 patients with partial responses (PR) lasting from 2.6 to 12.4 months; median progression-free survival was 5.5 months (90% CI 4.1 - 5.6); 7 patients (19%) were censored. Estimated overall survival rates at 12 and 24 months were 73% and 61%, respectively; and the combination was observed to be well tolerated, with AEs primarily related to chemotherapy. As previously reported, with completion of this phase 2 trial, the company does not have plans to advance into a phase 3 clinical trial in metastatic breast cancer in the absence of a partner. The company continues to focus on the eNRGy trial to potentially support a BLA submission seeking a tumor agnostic indication for Zeno in patients with previously treated NRG1+ cancers.

Neutral

Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022

2021-11-13 00:00:00

Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022. Venue: Amsterdam, Netherlands.

Neutral

Merus N.V. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-10 13:11:00

Merus N.V. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Negative

Merus N.V. has filed a Follow-on Equity Offering.

2021-11-04 00:00:00

Merus N.V. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock

Negative

Merus N.V. has completed a Follow-on Equity Offering in the amount of $110.000025 million.

2021-11-04 00:00:00

Merus N.V. has completed a Follow-on Equity Offering in the amount of $110.000025 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,859,650 Price\Range: $28.5 Discount Per Security: $1.71

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Positive

Merus N.V. Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

2021-10-07 13:00:00

Merus N.V. presented clinical data on MCLA-158, including clinical responses observed in advanced head and neck squamous cell carcinoma (HNSCC) and preclinical data on zenocutuzumab (Zeno) at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. MCLA-158 (petosemtamab): the reported data are from the ongoing phase 1 dose expansion cohort that is investigating the safety, tolerability, and anti-tumor activity of MCLA-158 monotherapy in advanced HNSCC. Observations in the presentation include: enrollment of 10 patients with advanced HNSCC, as of the safety and efficacy data cutoff date of August 9, 2021, with median age of 65 (range 50-77) years, and who were treated with a median of 2 lines of prior therapy. Seven patients were evaluable for an interim efficacy analysis by investigator assessment (three patients were enrolled <8 weeks from the cutoff date). Three of seven patients achieved partial responses, with one achieving complete response after the data cutoff date. Tumor reduction was observed in all seven patients. The safety profile of MCLA-158 was based on 29 patients with advanced solid tumors who were treated at 1500 mg every two weeks across the phase 1 trial. The most frequent adverse events (AEs) were infusion related reactions; 72% any grade, 7% grade = 3. Mild to moderate skin toxicity (3% grade =3). The company is planning its next update on the MCLA-158 trial in 2022. Zeno: observations in the preclinical presentation include: The bispecific HER2/HER3 antibody Zeno blocked cell growth 100 fold more potently than the bivalent HER3 antibody derived from Zeno, in an NRG1 driven growth assay. Zeno potently blocked NRG1-fusion mediated downstream signaling and growth in vitro and in vivo. Zeno induced both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated killing of cancer cells in a dose-dependent manner. As of September 1, 2021 more than 80 patients with NRG1 fusion cancers have been treated with Zeno monotherapy in the company's phase 1/2 eNRGy trial and Early Access Program.

Neutral

Merus N.V. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-07-2021 09:00 AM

2021-09-30 20:35:00

Merus N.V. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-07-2021 09:00 AM.

Neutral

Merus N.V. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 02:40 PM

2021-09-07 12:00:00

Merus N.V. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 02:40 PM. Venue: New York, United States. Speakers: Bill Lundberg, Chief Executive Officer.

Neutral

Merus N.V. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-07 12:00:00

Merus N.V. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Bill Lundberg, Chief Executive Officer.

Neutral

Merus N.V. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021 01:25 PM

2021-09-01 18:36:00

Merus N.V. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-09-2021 01:25 PM. Venue: New York, United States. Speakers: Bill Lundberg, CEO.

Neutral

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct 07, 2021 through Oct 11, 2021

2021-08-11 12:00:00

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct 07, 2021 through Oct 11, 2021.

Positive

Merus N.V. Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation

2021-07-21 12:00:00

Merus N.V. announced the novel mechanism of action (MOA) of MCLA-145, the Company’s clinical stage Biclonics® T-cell agonist. MCLA-145 binds with high affinity and specificity to PD-L1 and CD137. The unique immunostimulatory mechanism of action of MCLA-145 was published in Nature Communications on June 21, 2021, titled “A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context dependent T cell costimulation and checkpoint blockade.” MCLA-145 was identified by screening hundreds of bispecific IgG antibodies for immune activation via PD-L1 engagement among other characteristics. MCLA-145 was shown to potently activate T cells even in the presence of suppressive conditions. Furthermore, MCLA-145 was shown to enhance T cell priming and to promote long-term T cell immunity. These in vitro findings were translated to in vivo experiments where MCLA-145 anti-tumor activity was superior to the current standard immune checkpoint inhibitor comparators and linked to recruitment and intratumor expansion of CD8+ T cells. MCLA-145 is currently being evaluated in a phase 1 open-label, multicenter dose escalation study, including a planned safety dose expansion phase, in patients with solid tumors. MCLA-145 is the first drug candidate co-developed under Merus’ global collaboration and license agreement with Incyte, which permits the development and commercialization of up to 11 bispecific and monospecific antibodies from Biclonics® platform. Merus retains full rights to develop and commercialize MCLA-145, if approved, in the United States; and Incyte holds full rights to develop and commercialize MCLA-145 outside the United States.

Neutral

Merus N.V. Presents at Cambridge Health Institute PEGS Virtual Conference, Jul-19-2021 through Jul-22-2021

2021-07-16 13:36:00

Merus N.V. Presents at Cambridge Health Institute PEGS Virtual Conference, Jul-19-2021 through Jul-22-2021. Presentation Date & Speakers: Jul-19-2021, Pieter Fokko van Loo, Senior Director, Oncology – Immunology.

Neutral

Cambridge Healthtech Institute, Inc., Cambridge Health Institute PEGS Virtual Conference, Jul 19, 2021 through Jul 22, 2021

2021-07-16 12:52:00

Cambridge Healthtech Institute, Inc., Cambridge Health Institute PEGS Virtual Conference, Jul 19, 2021 through Jul 22, 2021.

Neutral

Merus N.V. Presents at William Blair Biotech Focus Conference 2021, Jul-14-2021 11:20 AM

2021-07-07 20:20:00

Merus N.V. Presents at William Blair Biotech Focus Conference 2021, Jul-14-2021 11:20 AM. Speakers: Sven Ante Lundberg, CEO, President, Principal Financial Officer & Executive Director.

Fundamental Summary

Merus's recently released results from Q1 indicate that Merus is performing reasonably well and on par with its peers. Its income and value factors appear positive and give support for optimism regarding the likelihood of continued positive performance. Therefore, Merus received an overall score of 64, translating into a HOLD ranking.

Merus reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 11.66 million compared to USD 8.35 million a year ago. Net loss was USD 18.89 million compared to USD 10.15 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 0.28 a year ago.

Business Description

Merus, a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Sector Overview

Merus is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Merus's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 417.5 17.3% 68
Liabilities 120.0 -20.1% 59
Price to Book 2.4 -43.0% 81
Cash & Equivalents 194.6 22.3% 83
Equity 297.5 44.6% 50
EBITDA -91.6 -6.7% 60
Total Revenues 52.4 20.7% 48
Parameter Value Change Score
Return on Equity -28.3 48.9% 59
Net Cashflow 19.9 0.0% 70
Capital Expenditure -1.0 0.0% 74
Asset Turnover 0.1 -15.7% 53
Free Cashflow -1.5 0.0% 71

* All values are TTM

The below chart reflects Merus's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Merus's peer average final assessment score stands on 62.0, Merus's score is 64.

  •  MRUS
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 8 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 9 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 10 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 11 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 12 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 13 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 15 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 16 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 17 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Merus's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Merus's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 62.

Neutral 62
Close Price 21.62
52W Low 13.98
52W High 32.29
5D MA 21.62
50D MA 19.57
200D MA 25.25
MACD 0.65
RSI 22.47
STOCH 69.11

Balance Sheet Analysis

Overall, Merus's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Merus did a great job related to cash and cash equivalents this period, which stood at 194.6, representing a 22.3% change from the previous filing. Its impressive cash and cash equivalents metrics should support upward pressure on its's stock price. Therefore, its cash and cash equivalents movement earned a score of 83. Also, Merus's price to book ratio (P/B) was reported as 2.4 and represents -43.0% change from the previous report. Their industry-leading book value factors momentum reinforces an expectation for future positive momentum for their stock price going forward. Consequently, their book value factors movement received a grade of 81. On the other hand, Equity, jumped out as looking rather underwhelming. Merus management produced disappointing equity metrics this period, which stood at 297.5, representing a 44.6% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Consequently, their equity movement received a grade of 50. Similarly, because the company's management is doing an excellent job managing these critical metrics, the balance sheet was given a score of 70.

Parameter Value Change Score
Assets 417.5 17.3% 68
Liabilities 120.0 -20.1% 59
Price to Book 2.4 -43.0% 81
Cash & Equivalents 194.6 22.3% 83
Equity 297.5 44.6% 50
* All values are TTM

The below chart describes Merus's performance as reflected on its balance sheet with respect to its peers. While Merus received a balance sheet score of 70, the average of its peers stands on 65.0.

  •  MRUS
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 8 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 9 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 10 1
CareDx, Inc 1.2B 54 67 52 39 51 52 11 1
MannKind Corporation 957.2M 79 59 50 40 64 57 12 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 14 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 15 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 16 1
Affimed N.V. 415.0M 56 66 63 56 47 54 17 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Merus's recently published income statement conveys disappointing growth, particularly with respect to Revenue Efficiency and Return Factors metrics. Merus reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 52.4 and represented 20.7% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. As a result, their revenue efficiency earned a score of 48. Also, Return factors metrics and ratios were disappointing in this report. Merus reported a return on equity (ROE) ratio of -28.3, representing a change of 48.9% from the last report.change of 48.9% from the previous period. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. They does not yet appear to be headed in the right direction regarding these return on equity and return on assets metrics. Its return factors (ROA & ROE) components, therefore, received a grade of 59. However, one encouraging metric, EBITDA, stood out. Merus's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as -91.6, which represents a -6.7% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. Therefore, its EBITDA component earned a score of 60. Therefore, it received a cautionary score of 54.

Parameter Value Change Score
EBITDA -91.6 -6.7% 60
Total Revenues 52.4 20.7% 48
Return on Equity -28.3 48.9% 59
* All values are TTM

The below chart describes Merus's performance as reflected on its income statement with respect to its peers. While Merus received a income statement score of 54 , the average of its peers stands on 60.0.

  •  MRUS
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 8 1
Veracyte, Inc. 1.4B 45 63 57 55 9 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 10 1
CareDx, Inc 1.2B 61 44 82 50 11 1
MannKind Corporation 957.2M 95 48 56 61 12 1
Amarin Corporation plc 734.5M 95 44 82 63 13 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 15 1
Radius Health, Inc. 499.8M 94 71 68 82 16 1
Affimed N.V. 415.0M 95 49 75 66 17 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Overall, Merus's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Merus's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -1.0, which represents a 0.0% change from the last period. This performance is all the more impressive relative to their peers and competitors. The company's CapEx movement, therefore, received a grade of 74. Also, Merus's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. Merus recorded free cash flow of -1.5, which represents a 0.0% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. Their free cash flow situation is all the more impressive relative to their peers and competitors. Therefore, its free cash flow movement earned a score of 71. At the same time, one critical cash flow metric, Asset Turnover, was notably weak. Merus's asset turnover numbers were discouraging, reflecting significant concerns related to management's ability to leverage assets to generate sales effectively and efficiently. Merus recorded asset turnover of 0.1, which represents a -15.7% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. The company's asset turnover metrics seem especially problematic relative to their peers. Therefore, their asset turnover movement earned a score of 53. Therefore, we scored their cash flow a 71.

Parameter Value Change Score
Net Cashflow 19.9 0.0% 70
Capital Expenditure -1.0 0.0% 74
Asset Turnover 0.1 -15.7% 53
Free Cashflow -1.5 0.0% 71
* All values are TTM

The below chart describes Merus's performance as reflected on its cash flow with respect to its peers. While Merus received a cash flow score of 71, the average of its peers stands on 66.0.

  •  MRUS
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 8 1
Veracyte, Inc. 1.4B 90 95 46 46 82 9 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 10 1
CareDx, Inc 1.2B 98 84 40 50 86 11 1
MannKind Corporation 957.2M 77 56 43 37 66 12 1
Amarin Corporation plc 734.5M 52 40 74 55 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 14 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 15 1
Radius Health, Inc. 499.8M 64 40 37 56 57 16 1
Affimed N.V. 415.0M 72 57 95 43 74 17 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.